Immunoprecipitation (IP) is a common research technique used to precipitate a specific protein (or protein complex) of interest out of a heterogeneous lysate. The concept of precipitating proteins out of solution is often called a "pull-down". There are a variety of methods to achieve immunoprecipitation, the most common of which uses antibodies bound to magnetic or agarose beads. This process can be used to isolate and concentrate a particular protein or complex from a sample containing many thousands of different proteins, and is often used to study protein-protein interactions through Co-IP experiments.
Novus offers a range of support options for IP when you buy a product to help you with your IP experiment including:
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Biotin | NB100-1365 | |||
| FITC | NB100-1183-0.025mg | |||
| FITC | NB100-1183 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-80652-0.1mg | |||
| BSA Free | NB100-77417SS | |||
| Azide and BSA Free | NBP2-80652 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-55288SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-24911 | |||
| BSA Free | NB100-56559SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-302SS | |||
| Azide and BSA Free | NBP2-80675 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-268SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB500-179SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-594SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-1335SS | |||
| Azide and BSA Free | NBP2-80745 | |||
![Immunocytochemistry/Immunofluorescence: GFP Antibody [NB600-303] - Analysis of FITC conjugate of NB600-303. Staining of mouse spleen cells Tissue: spleen cells infected with MHV68-H2bYFP. As seen in: Collins CM, Speck SH (2012) Tracking Murine Gammaherpesvirus 68 Infection of Germinal Center B Cells.](http://images.novusbio.com/fullsize/GFP-Antibody-Immunocytochemistry-Immunofluorescence-NB600-303-img0023.jpg "Immunocytochemistry/Immunofluorescence: GFP Antibody [NB600-303] - Analysis of FITC conjugate of NB600-303. Staining of mouse spleen cells Tissue: spleen cells infected with MHV68-H2bYFP. As seen in: Collins CM, Speck SH (2012) Tracking Murine Gammaherpesvirus 68 Infection of Germinal Center B Cells.")
![Western Blot: GFP Antibody [NB600-303] - Analysis using the FITC conjugate of NB600-303. Detection of Lane 1: GFP. Load: 50 ug per lane. Primary antibody: none. Secondary antibody: Fluorescein conjugated Anti-GFP at 1:1000 for 60 min at RT. Block: 1% BSA-TTBS for 30 min at RT. Predicted/Observed size: 28 kDa, 28 kDa.](http://images.novusbio.com/fullsize/GFP-Antibody-Western-Blot-NB600-303-img0018.jpg)
![Western Blot: GFP Antibody [NB600-303] - WB analysis of GFP in various lysates. Image courtesy of product review by Emilie Leclerc.](http://images.novusbio.com/fullsize/GFP-Antibody-Western-Blot-NB600-303-img0005.jpg)
![Immunoprecipitation: GFP Antibody [NB600-303] - IP analysis of GFP in HeLa cell lysate. Image courtesy of anonymous customer review.](http://images.novusbio.com/fullsize/GFP-Antibody-Immunoprecipitation-NB600-303-img0007.jpg)
![Western Blot: GFP Antibody [NB600-303] - Analysis of GFP HRP expression in HeLa/GFP cell lysate.](http://images.novusbio.com/fullsize/GFP-Antibody-Western-Blot-NB600-303-img0014.jpg)
![Western Blot: GFP Antibody [NB600-303] - Analysis using Biotin conjugate of NB600-303. Lane 1: 50ng of GFP. Lane 2: none. Primary antibody: none. Secondary antibody: Anti- Biotin Conjugated secondary antibody was used at 1:5000 in Blocking Buffer for Fluorescent Western Blotting for 45 min at RT. HRP Streptavidin was used at 1:40,000 in incubated with blocking buffer for 30 min at 20C. Block: 5% Blotto 30 min at 20C. Predicted/Observed size: 28 kDa for GFP. Other band(s): none.](http://images.novusbio.com/fullsize/GFP-Antibody-Western-Blot-NB600-303-img0019.jpg)
![Immunohistochemistry: GFP Antibody [NB600-303] - Eight-week-old Lgr5-GFP mice were injected with CCL4 and rHGF or/and rRspo1 proteins (0.1 ug/mice/time), as indicated in a, Lgr5 expression was measured using an immunofluorescent assay with anti-GFP antibody. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-017-01341-6) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GFP-Antibody-Immunohistochemistry-NB600-303-img0024.jpg)
![Western Blot: GFP Antibody [NB600-303] - Lane 1: 293FT cells transfected with CDK4 dominant negative. Lane 2: 293FT cells poitive control. Load: 25 ug per lane. Primary antibody: GFP antibody at 1:400 for overnight at 4C. Secondary antibody: IRDye800 (TM) rabbit secondary antibody at 1:10,000 for 45 min at RT. Block: 5% BLOTTO overnight at 4C. Predicted/Observed size: 27 kDa for GFP.](http://images.novusbio.com/fullsize/GFP-Antibody-Western-Blot-NB600-303-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: GFP Antibody [NB600-303]](http://images.novusbio.com/fullsize/GFP-Antibody-Immunocytochemistry-Immunofluorescence-NB600-303-img0022.jpg)
![Western Blot of Rabbit anti-GFP antibody. Lane 1: Wild type GFP (0.1 ug) was used to spike HeLa whole cell lysate. Lane 2: none. Load: 30 ug per lane. Primary antibody: GFP antibody at 1:1000 for overnight at 4C. Secondary antibody: IRDye800(TM) Goat-a-Rabbit IgG [H&L] MX10 () at 1:10,000 for 45 min at RT. Block: 5% BLOTTO in PBS overnight at 4C. Predicted/Observed size: 27 kDa for epitope tag GFP. Other band(s): none.](http://images.novusbio.com/fullsize/nb600-303_rabbit-polyclonal-gfp-antibody-24520231052434.jpg)
![Western Blot: GFP Antibody [NB600-303] - The polo-boxes of Plk4 are not sufficient to mediate STIL binding.(A) Scheme of Flag-Plk4 fragments. (B) After overexpression of Flag-Plk4-fragments (A) & GFP-STIL in HEK293T cells, cell lysates were subjected to immunoprecipitations using anti-Flag antibodies. Coprecipitation of GFP-STIL with Flag-Plk4 fragments was detected by western blotting using anti-GFP & anti-Flag antibodies. Image collected & cropped by CiteAb from the following publication (//journals.biologists.com/bio/article/4/3/370/1390/Plk4-dependent-phosphorylation-of-STIL-is-required), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-303_rabbit-polyclonal-gfp-antibody-31020241529192.jpg)
![Immunocytochemistry/ Immunofluorescence: GFP Antibody [NB600-303] - Lgr5+ liver stem cells transplantation decreased liver fibrosis. a Schematic overview of the experimental setup. Eight-week-old wild-type C57 mice were i.p. injected with CCL4 (2 ml/kg, Sigma-Aldrich) dissolved in olive oil at a ratio of 1:4, or olive oil alone (2 ml/kg) twice a week for 6 weeks. Lgr5-GFP+ liver stem cells or primary hepatocyte (PH) derived from Lgr5-GFP mice were transplanted into the liver fibrosis mice by intrasplenical injection on day 0. b Lgr5+ cells were isolated from Lgr5-GFP mice treated with CCL4 by FACS assay for transplantation (left). The liver Lgr5 expression was stained using anti-GFP antibody in mice with Lgr5+ cells or PH transplantation (right) on day 40. n = 10 mice, scale bars, 200 μm. c, d Lgr5+ liver stem cells transplantation decreased CCL4-induced liver fibrosis & recovered liver functions. Lgr5-GFP+ liver stem cells or PH transplantation were described in a; the livers were harvested & stained using H&E & Sirius Red for fibrosis analysis & quantification of positive-staining areas measured by Image J software (c). The serum was harvested for ALT & AST analysis (d, e). For c, scale bars, 200 μm, the results are shown as mean ± s.d. of five independent sections taken randomly per mice & a total of 50 tissue specimens in each group (n = 10 mice) *p < 0.05, **p < 0.01. For d, e, triplicates for each condition were analyzed. The results are shown as mean ± s.d. of three independent experiments. *p < 0.05, **p < 0.01 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29079780), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-303_rabbit-polyclonal-gfp-antibody-31020241616099.jpg)
![Flow Cytometry: CD45 Antibody (30-F11) [NB100-77417] - Analysis of CD45 (30F11) in freshly isolated mouse (Balb C) splenocytes (1x10^6) were stained with [NB100-77417] at 1:1000 dilution and detected with FITC conjugated donkey anti-rat IgG secondary (orange). Shown with rat IgG isotype control (blue).](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Flow-Cytometry-NB100-77417-img0004.jpg "Flow Cytometry: CD45 Antibody (30-F11) [NB100-77417] - Analysis of CD45 (30F11) in freshly isolated mouse (Balb C) splenocytes (1x10^6) were stained with [NB100-77417] at 1:1000 dilution and detected with FITC conjugated donkey anti-rat IgG secondary (orange). Shown with rat IgG isotype control (blue).")
![Immunohistochemistry-Paraffin: CD45 Antibody (30-F11) [NB100-77417] - Analysis of FFPE section of mouse spleen using rat monoclonal CD45 antibody (30-F11) [NB100-77417] at 1:50 dilution. The antibody generated an expected membrane staining in the red and white pulp spleenocytes of the tested spleen section.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-Paraffin-NB100-77417-img0006.jpg)
![Immunohistochemistry-Paraffin: CD45 Antibody (30-F11) [NB100-77417] - Mouse glomeruli stained with CD45 antibody. 4% formaldehyde fixed paraffin sections. EDTA was used for antigen retrieval. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-Paraffin-NB100-77417-img0013.jpg)
![Immunohistochemistry: CD45 Antibody (30-F11) [NB100-77417] - Analysis of a FFPE embedded tissue section of mouse liver using 1:100 dilution of CD45 antibody (30-F11) [NB100-77417]. The signal was developed using AEC reagent based method with hematoxylin counterstaining.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-NB100-77417-img0003.jpg)
![Immunohistochemistry-Frozen: CD45 Antibody (30-F11) [NB100-77417] - Analysis of a mouse spleen cryosection using CD45 antibody (30-F11) [NB100-77417] at 1:50 dilution. The signal was detected using goat anti-rat Alexa fluor 488 secondary with DAPI counterstaining. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-Frozen-NB100-77417-img0008.jpg)
![Immunohistochemistry-Paraffin: CD45 Antibody (30-F11) [NB100-77417] - Staining of a FFPE mouse liver tissue section using 1:100 dilution of CD45 antibody (30-F11) [NB100-77417]. Signal was detected using AF488 conjugated donkey anti-rat secondary antibody at 1:500 dilution. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-Paraffin-NB100-77417-img0002.jpg)
![Immunohistochemistry: CD45 Antibody (30-F11) [NB100-77417] - Severe apoptosis and pathology in the orally infected heart. Experimental design is as outlined in Fig. 1B. Heart sections from moribund mice were examined with H&E, and immunohistochemistry staining for pan-leukocyte infiltration using an anti-CD45 antibody. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-47455-3), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-NB100-77417-img0009.jpg)
![Immunohistochemistry: CD45 Antibody (30-F11) [NB100-77417] - Severe apoptosis and pathology in the orally infected heart. Experimental design is as outlined in Fig. 1B. Heart sections from moribund mice were examined with H&E, and immunohistochemistry staining for pan-leukocyte infiltration using an anti-CD45 antibody. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-47455-3), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-NB100-77417-img0012.jpg)
![Immunohistochemistry: CD45 Antibody (30-F11) [NB100-77417] - VP1-positive infiltrating M2 macrophage and VP1-positive pneumocytes were detectable in the orally infected lung. Adjacent lung sections were examined with H&E and IHC staining for a pan-leukocyte marker CD45. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-47455-3), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-NB100-77417-img0011.jpg)
![Western Blot: DRP1 Antibody [NB110-55288] - Total protein from human HeLa and MCF7 cells, mouse 3T3 cells and rat PC12 cells was separated on a 7.5 % gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-DRP1 in blocking buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/DRP1-Antibody-Western-Blot-NB110-55288-img0012.jpg "Western Blot: DRP1 Antibody [NB110-55288] - Total protein from human HeLa and MCF7 cells, mouse 3T3 cells and rat PC12 cells was separated on a 7.5 % gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-DRP1 in blocking buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
![Immunohistochemistry-Paraffin: DRP1 Antibody [NB110-55288] - Analysis of FFPE tissue section of mouse kidney using DRP1 antibody #NB110-55288 at 1:300. The primary antibody bound to DRP1 protein in the tissue section was detected using a HRP labeled secondary antibody and DAB reagent. Nuclei of the cells were counterstained with hematoxylin. This antibody generated a diffused cytoplasmic staining of DRP1 in the epithelial cells of various tubules and in the cells of glomeruli.](http://images.novusbio.com/fullsize/DRP1-Antibody-Immunohistochemistry-Paraffin-NB110-55288-img0013.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: DRP1 Antibody [NB110-55288] - Lane 1: DRP1 knockout. Lane 2: DRP1 wildtype MEFs. Stained with NB110-55288 at 1:500.](http://images.novusbio.com/fullsize/DRP1-Antibody-Western-Blot-NB110-55288-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: DRP1 Antibody [NB110-55288] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton X-100. The cells were incubated with anti-DRP1 at 5 ug/mL overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/DRP1-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55288-img0015.jpg)
![Immunohistochemistry: DRP1 Antibody [NB110-55288] - Staining of renal tubular epithelium and visceral epithelial cells of the glomerulus. Human kidney cortex, 40X magnification.](http://images.novusbio.com/fullsize/DRP1-Antibody-Immunohistochemistry-NB110-55288-img0005.jpg)
![Western Blot: DRP1 Antibody [NB110-55288] - Assessment of skeletal muscle mitochondrial dynamic markers. Representative western blots. Significant main effect of training: #, p < 0.05; ##, p < 0.01. Significant post-hoc training effect: *, p < 0.05; **, p < 0.01. Data are presented as mean +/- SEM. Image collected and cropped by CiteAb from the following publication (null), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/DRP1-Antibody-Western-Blot-NB110-55288-img0019.jpg)
![Immunocytochemistry/Immunofluorescence: DRP1 Antibody [NB110-55288] - PC12 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti-DRP1 Antibody at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/DRP1-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55288-img0017.jpg)
![Flow Cytometry: DRP1 Antibody [NB110-55288] - An intracellular stain was performed on HeLa cells with DRP1 Antibody NB110-55288AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/DRP1-Antibody-Flow-Cytometry-NB110-55288-img0018.jpg)
![Western Blot: DRP1 Antibody [NB110-55288] - Rat spinal cord-DRP1 (81kda). Image from verified customer review.](http://images.novusbio.com/fullsize/DRP1-Antibody-Western-Blot-NB110-55288-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: DRP1 Antibody [NB110-55288] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-DRP1 at 5.0 ug/mL overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at 1:500. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at 1:1000 and detected with an anti-mouse Dylight 550 (Red) at 1:500. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/DRP1-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55288-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: DRP1 Antibody [NB110-55288] - NIH3T3 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti-DRP1 Antibody at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/DRP1-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55288-img0016.jpg)
![Flow Cytometry: DRP1 Antibody [NB110-55288] - An intracellular stain was performed on HeLa cells with NB110-55288 and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550.](http://images.novusbio.com/fullsize/DRP1-Antibody-Flow-Cytometry-NB110-55288-img0014.jpg)
![Simple Western: DRP1 Antibody [NB110-55288] - Image shows a specific band for DUX4 in 0.5 mg/mL of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/DRP1-Antibody-Simple-Western-NB110-55288-img0008.jpg)
![Simple Western: DRP1 Antibody - BSA Free [NB110-55288] - Image shows a specific band for DRP1 in 0.1 ug/uL mouse hippocampus tissue lysate. Primary antibody dilution: 1:200. Image from verified customer review.](http://images.novusbio.com/fullsize/DRP1-Antibody---BSA-Free-Simple-Western-NB110-55288-img0020.jpg)
![Western Blot: S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - Analysis using Azide Free version of NB100-56559. Psoriasin in A) MCF10A and B) MCF7 cell lysate using psoriasin antibody at 1 ug/mL.](http://images.novusbio.com/fullsize/S100A7-Psoriasin-Antibody-47C1068-Western-Blot-NB100-56559-img0014.jpg "Western Blot: S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - Analysis using Azide Free version of NB100-56559. Psoriasin in A) MCF10A and B) MCF7 cell lysate using psoriasin antibody at 1 ug/mL.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry: S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - Activities of proinflammatory cytokines on the differentiation of Reconstituted Human Epidermis. RHE have been cultured for 10 days at the air-water interface using an appropriate differentiation medium and then with or without recombinant IL-1alpha, IL-17A, IL-22, OSM or TN alpha alone or in combination during 72 h for immunohistological analysis. RHE were fixed, embedded in paraffin and 4 um vertical sections were stained with Hematoxylin and Eosin (HE) or with anti-CK10, anti-LOR, anti-FLG, anti-IVL or anti-S100A7 mAbs. Results are from one experiment representative of two. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0101937), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/S100A7-Psoriasin-Antibody-47C1068-Immunohistochemistry-NB100-56559-img0018.jpg)
![Immunocytochemistry/Immunofluorescence: S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - S100A7/psoriasin detection was performed on (A) untreated and (B) LPS-treated (100 ng/mL, 21 hrs) HOPE-fixed NCI-H727 cells using the monoclonal Psoriasin/HID5/S100A7 antibody (NB100-56559). (C) Positive control is shown by the expression of the nuclear Ki67 antigen with the MIB-1 (2 ug/mL) antibody. (D) Negative control was included omitting the primary antibody.](http://images.novusbio.com/fullsize/S100A7-Psoriasin-Antibody-47C1068-Immunocytochemistry-Immunofluorescence-NB100-56559-img0005.jpg)
![Immunohistochemistry: S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - Inhibition of KDM expression in vivo. Skin biopsies from normal control skin (Cont) or lesional psoriatic skin (Pso) were collected. Skin sections were stained with Hematoxylin and immunodetection of cytokeratin 10, loricrin, filaggrin, involucrin and S100A7 was performed. Scale bar 100 um. Results are from one experiment representative of three. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0101937), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/S100A7-Psoriasin-Antibody-47C1068-Immunohistochemistry-NB100-56559-img0019.jpg)
![Flow (Intracellular): S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - An intracellular stain was performed on Jurkat cells with S100A7/Psoriasin antibody (47C1068) NBP2-24911PE (blue) and a matched isotype control NBP2-27287PE (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin.. Using the PE format of this antibody.](http://images.novusbio.com/fullsize/S100A7-Psoriasin-Antibody-47C1068-Flow-Intracellular-NB100-56559-img0020.jpg)
![Immunohistochemistry-Paraffin: S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - Staining of human skin. FFPE tissue after heat-induced antigen retrieval. Antibody concentration 10 ug/mL.](http://images.novusbio.com/fullsize/S100A7-Psoriasin-Antibody-47C1068-Immunohistochemistry-Paraffin-NB100-56559-img0006.jpg)
![Immunohistochemistry-Paraffin: S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - Tissue section of human esophageal squamous cell carcinoma (SCC) using 5 ug/mL concentration of Psoriasin/S100A7 antibody (clone 47C1068). Diffused to granular cytoplasmic immunostaining was observed all over the tissue section with highest expression levels in the areas with cancer cells especially in the developing squamous keratin pearls.](http://images.novusbio.com/fullsize/S100A7-Psoriasin-Antibody-47C1068-Immunohistochemistry-Paraffin-NB100-56559-img0008.jpg)
![Immunohistochemistry-Paraffin: S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - Analysis of FFPE tissue section of human lymph node cancer using 5 ug/mL concentration of Psoriasin/S100A7 antibody (clone 47C1068). Very strong cytoplasmic immunopositivity of Psoriasin/S100A7 protein was observed in the cancer cells.](http://images.novusbio.com/fullsize/S100A7-Psoriasin-Antibody-47C1068-Immunohistochemistry-Paraffin-NB100-56559-img0009.jpg)
![Immunohistochemistry-Paraffin: S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - Human breast tissue stained with psoriasin antibody at 1:200 using peroxidase-conjugate and DAB chromogen. Antigen retrieval with citrate buffer, pH 6.](http://images.novusbio.com/fullsize/S100A7-Psoriasin-Antibody-47C1068-Immunohistochemistry-Paraffin-NB100-56559-img0011.jpg)
![Flow (Intracellular): S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - An intracellular stain was performed on Jurkat cells with S100A7/Psoriasin antibody (47C1068) NBP2-24911PE (blue) and a matched isotype control NBP2-27287PE (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin.](http://images.novusbio.com/fullsize/S100A7-Psoriasin-Antibody-47C1068-Flow-Intracellular-NB100-56559-img0017.jpg)
![Simple Western: S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - Image shows a specific band for S100A7/Psoriasin in 0.5 mg/mL of MCF-7 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/S100A7-Psoriasin-Antibody-47C1068-Simple-Western-NB100-56559-img0010.jpg)
![Simple Western: S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - Analysis using Azide Free version of NB100-56559. Image shows a specific band for Psoriasin/S100A7 in 0.05 mg/mL of MCF-7 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/S100A7-Psoriasin-Antibody-47C1068-Simple-Western-NB100-56559-img0015.jpg)
![Western Blot: S100A7/Psoriasin Antibody (47C1068) - BSA Free [NB100-56559] - S100A7 activated p53 related anti-proliferative pathways. (A) Log2 fold change of mRNA expression of p53 pathway factors after S100A7 overexpression. (B) WB of p53 & S100A7 in MCF7-p53-CKD transfected with S100A7 or vector control. p53 shRNA transcription & p53 knockdown in MCF7-p53-CKD was induced by Doxycyclin (Dox). (C) S100A7 activated p53, ATR, chk-1, chk-2 in MCF7 cells. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25622979), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56559_mouse-monoclonal-s100a7-psoriasin-antibody-47c1068-31020241529196.jpg)
![Western Blot: S100A7/Psoriasin Antibody (47C1068) - BSA Free [NB100-56559] - S100A7 induces EMT in cervical cancer cellsWestern Blot showed the protein level of epithelial marker E-cadherin & mesenchymal markers (N-Cadherin, Vimentin, Fibronectin) & EMT transcription factors Snail & Slug after overexpression of S100A7 in C33A cells A. & SiHa cells B. beta -actin is used as a loading control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.15329), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56559_mouse-monoclonal-s100a7-psoriasin-antibody-47c1068-310202415334934.jpg)
![Western Blot: S100A7/Psoriasin Antibody (47C1068) - BSA Free [NB100-56559] - S100A7 interacts with RAGE, stimulates ERK pathway & RAGE mediates S100A7-induced migration & invasion in C33A & SiHa cellsA. HEK293 cells were transiently co-expressed with pcDNA3-Flag & pcDNA3-Flag-RAGE with pcDNA3-myc-S100A7. Cell extracts were immunoprecipitated separately with specific antibody against Flag, & the associated Flag-RAGE & myc-S100A7 were examined by Western blotting using tagged antibodies, respectively. B. S100A7-expressing cells were found to have higher levels of phospho-ERK (without any change in total ERK levels). In comparison, the levels of phospho-Akt & phospho-NF-kappa B had no obvious change. C. qRT-PCR verification of RAGE knockdown by two independent siRNAs in C33A & SiHa cells. D&E. RAGE knockdown suppressed migration & invasion in S100A7-overexpressed C33A & SiHa cells & their corresponding control cells. The stained cells were manually counted from 4 randomly selected fields & normalized with cell proliferation [2-sided t test; * P < 0.05; **P < 0.01]. Representative image & quantitative results of cell migration & invasion were shown (D. C33A cells; E. SiHa cells; ×10, bars: 100μm). Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.15329), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56559_mouse-monoclonal-s100a7-psoriasin-antibody-47c1068-31020241555244.jpg)
![Western Blot: S100A7/Psoriasin Antibody (47C1068) - BSA Free [NB100-56559] - S100A7 is secreted & acts as a chemotactic factor of cell migration & invasionA. Cells were cultured in serum-free medium for 2 days, then the medium was collected, fractioned, followed by Western Blot analysis. B&C. Transwell migration & Matrigel invasion assays were performed in C33A & SiHa cells. Cell suspension was placed into the upper chamber in 0.1 ml of DMEM serum-free medium, & conditioned medium from S100A7-overexpressed C33A & SiHa cells & their corresponding control cells was placed in the lower chamber as a chemoattractant. The stained cells were manually counted from 4 randomly selected fields & normalized with cell proliferation [2-sided t test; *P < 0.05; ***P < 0.001]. Representative image & quantitative results of cell migration & invasion were shown (B. C33A cells; C. SiHa cells; ×10, bars:100μm). Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.15329), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56559_mouse-monoclonal-s100a7-psoriasin-antibody-47c1068-310202415535176.jpg)
![Western Blot: S100A7/Psoriasin Antibody (47C1068) - BSA Free [NB100-56559] - S100A7 promotes cervical cancer cell migration & invasionA&B. Establishment of stable cell lines of ectopic expression of S100A7. C33A & SiHa cells were infected with pLVX-Con & pLVX-S100A7 lentivirus, stable cells were established by Geneticin (G418) selection for about 2 weeks. Cells were harvested, S100A7 expression was detected by qRT-PCR (A: [mean (n=2) ± SD; 2-sided t test; ** P<0.01, normalized to beta -actin]) & Western Blot. C&D. Transwell migration & Matrigel invasion assays were performed in S100A7-overexpressed cells & their corresponding control cells. The stained cells were manually counted from 4 randomly selected fields & normalized with cell proliferation [2-sided t test; **P < 0.01]. Representative image & quantitative results of cell migration & invasion were shown (C. C33A cells; D. SiHa cells; ×10, bars:100μm). E. The effect of S100A7 on cell migration was examined in wound-healing assay. Confluent cells were scratched & photographed at time 0h & 48h (Left panel. C33A cells; Right panel. SiHa cells. ×10, bars:100μm). Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.15329), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56559_mouse-monoclonal-s100a7-psoriasin-antibody-47c1068-310202415541988.jpg)
![Immunocytochemistry/Immunofluorescence: Synapsin I Antibody [NB300-104] - hPDLSCs-derived neural-like cells are connected by synapse-like interactions. hPDLSCs-derived neural-like cells connect to one another. Synapse-associated protein Synapsin1 is found in the cell membrane of hPDLSCs-derived neural-like cells at the neurite contact areas. Scale bar: 25 um. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-54745-3) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Synapsin-I-Antibody-Immunocytochemistry-Immunofluorescence-NB300-104-img0013.jpg "Immunocytochemistry/Immunofluorescence: Synapsin I Antibody [NB300-104] - hPDLSCs-derived neural-like cells are connected by synapse-like interactions. hPDLSCs-derived neural-like cells connect to one another. Synapse-associated protein Synapsin1 is found in the cell membrane of hPDLSCs-derived neural-like cells at the neurite contact areas. Scale bar: 25 um. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-54745-3) licensed under a CC-BY license.")
![<b>Orthogonal Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: Synapsin I Antibody [NB300-104] - Characterization of WT and slow ESCs differentiated to neurons. Immunofluorescence staining for neuronal markers Map2, and Syn1 in neurons cultured on poly-ornithine-/laminin-coated plates. Expression of neuronal markers in neurons cultured on poly-ornithine-/laminin-coated plates from RNA-seq analysis, n = 3. Image collected and cropped by CiteAb from the following publication (//onlinelibrary.wiley.com/doi/10.15252/embj.2018101244) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Synapsin-I-Antibody-Immunocytochemistry-Immunofluorescence-NB300-104-img0014.jpg)
![Western Blot: Synapsin I Antibody [NB300-104] - Western blot analysis showing induced expression of neuronal functional marker Synapsin I at protein levels in MNC (meningial neuronal construct). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30443545/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Synapsin I Antibody-Western Blot-NB300-104-img0015.jpg)
![Immunohistochemistry-Paraffin: Synapsin I Antibody [NB300-104] - Human cerebellum section, formalin fixed paraffin embedded. Stained with Synpasin-1 at 1:250. Citrate antigen retrieval at pH 6. Image from verified customer review.](http://images.novusbio.com/fullsize/Synapsin-I-Antibody-Immunohistochemistry-Paraffin-NB300-104-img0012.jpg)
![Western Blot: Synapsin I Antibody [NB300-104] - 10 ug of rat hippocampal (Hipp) lysate showing specific immunolabeling of the ~78k synapsin I doublet protein.](http://images.novusbio.com/fullsize/Synapsin-I-Antibody-Western-Blot-NB300-104-img0007.jpg)
![Western Blot: Synapsin I Antibody [NB300-104] - 10 ug of rat brain lysate showing specific immunolabeling of the ~78 kDa Synapsin I doublet.](http://images.novusbio.com/fullsize/Synapsin-I-Antibody-Western-Blot-NB300-104-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: Synapsin I Antibody [NB300-104] - ICC-IF validation analysis of Synapsin 1 Antibody on cultured rat caudate neurons. This representative image shows the punctate distribution of Synapsin 1 (green) and MAP (red) proteins in a neuronal cell.](http://images.novusbio.com/fullsize/Synapsin-I-Antibody-Immunocytochemistry-Immunofluorescence-NB300-104-img0011.jpg)
![Immunocytochemistry/ Immunofluorescence: Synapsin I Antibody [NB300-104] - Characterization of WT & slow ESCs differentiated to neurons (related to Fig 4)Immunofluorescence staining for neuronal markers Map2, Syn1, & NeuN in neurons cultured on poly‐ornithine‐/laminin‐coated plates.Expression of neuronal markers in neurons cultured on poly‐ornithine‐/laminin‐coated plates from RNA‐seq analysis, n = 3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30988016), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-104_rabbit-polyclonal-synapsin-i-antibody-310202415394528.jpg)
![Immunocytochemistry/ Immunofluorescence: Synapsin I Antibody [NB300-104] - hPDLSCs-derived neural-like cells are connected by synapse-like interactions. hPDLSCs-derived neural-like cells connect to one another (a) through different types of synapses-like interactions, including dendrodendritic-like, axoaxonic-like & axodendritic-like synapses (b). (c) Synapse-associated proteins Cx43, Synaptophysin & Synapsin1 are found in the cell membrane of hPDLSCs-derived neural-like cells at the neurite contact areas. Scale bar: 25 μm. AA, axoaxonic-like synapse; AD, axodendritic-like synapse; DD, dendrodendritic-like synapse; LM, light microscopy; SEM, scanning electron microscopy. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31792338), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-104_rabbit-polyclonal-synapsin-i-antibody-310202415371980.jpg)
![Western Blot: Synapsin I Antibody [NB300-104] - Synaptic localization of TA at the PC–PF synaptic contacts.Western blot of TA, V1, V2, VGAT proteins in cerebellar synaptosomal fractions (SYN) from P14 mice. Synaptosomal preparations are enriched of post synaptic density protein (PSD95) & Synapsin-I (Syn-I) in comparison to equal amount (ACT) of total cerebellar protein extract (LYS). TA is clearly present in synaptosomal enriched preparations. B) Cerebellar sagittal section immunostained for Cb (green), V1 (cyan) & TA (red). In the ML, anti-V1 specifically labels PF-terminals contacting PC-spines. C–E) The high magnification of the inset in B is reproduced in different merge images & by the relative split channels. C) Merge image of Cb & V1 staining plus the colocalization mask Cb/V1 (mCb/V1 in white); it represents the negative CTR (CTR-). D) Merge image of TA & Cb staining plus the colocalization mask TA/Cb (mTA/Cb in white), highlighting TA expression in PC-spines. E) Merge image of TA & V1 staining plus the colocalization mask TA/V1 (m TA/V1 in white), indicating the presence of TA also in this synaptic terminal. F) Quantitative colocalization analysis shows the mean overlap coefficients of TA/Cb (gray column) & TA/V1 (black column) significantly different from the negative CTR Cb/V1 (white column). The small insets (white boxes in C–D-E) are high magnifications of a representative PC-spine (green) contacted by a PF synaptic terminal (cyan) with the appropriate colocalization mask (white). * p < 0.05. Data are represented as mean ± SEM. Scale bars in B, 10 µm; in C–D-E, 5 µm; in F, 1 µm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23840813), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-104_rabbit-polyclonal-synapsin-i-antibody-31020241621237.jpg)
![Western Blot: Synapsin I Antibody [NB300-104] - Tau oligomers induce synaptic dysfunction. (A) Representative Western blot of mouse hippocampus homogenate. The levels of synaptophysin, synapsin-1, & septin-11 were measured by band quantification & normalized with the levels of tubulin. PBSo indicates representative bands of hippocampal area injected with PBS in mice also injected with tau oligomers, PBSf indicates PBS injection in mice also injected with tau fibrils, & PBSm indicates PBS injection in mice also injected with tau monomers. (B) Synaptophysin levels were significantly lower in the hemispheres injected with tau oligomers in comparison with the ones injected with fibrils, monomers, or PBS. (C) No significant differences in the levels of synapsin-1 were observed. (D) Only the hemisphere injected with tau oligomers presents a decrease in the level of septin-11. Data are represented as the mean ± SE. *p < 0.01, n = 6 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21645391), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-104_rabbit-polyclonal-synapsin-i-antibody-31020241620516.jpg)
![Western Blot: c-Myc Antibody (9E10) [NB600-302] - CtIP is phosphorylated by CDKs at multiple sites. Myc-BRCA1 and/or HA-CtIP WT or indicated mutants were expressed in 293T cells and co-immunoprecipitation was performed. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pgen.1003277) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Western-Blot-NB600-302-img0022.jpg "Western Blot: c-Myc Antibody (9E10) [NB600-302] - CtIP is phosphorylated by CDKs at multiple sites. Myc-BRCA1 and/or HA-CtIP WT or indicated mutants were expressed in 293T cells and co-immunoprecipitation was performed. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pgen.1003277) licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: c-Myc Antibody (9E10) [NB600-302] - c-Myc was detected in immersion fixed paraffin-embedded sections of human breast cancer using anti-human mouse monoclonal antibody (Catalog # NB600-302, clone 9E10) at 1:50 dilution overnight at 4 C. Tissue was stained using the VisuCyte anti-mouse HRP polymer detection reagent (Catalog # VC001) with DAB chromogen (brown) and counterstained with hematoxylin (blue). Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Immunohistochemistry-Paraffin-NB600-302-img0009.jpg)
![Simple Western: c-Myc Antibody (9E10) [NB600-302] - Simple Western lane view shows a specific band for c-Myc in 0.5 mg/ml of Jurkat lysate. This experiment as performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Simple-Western-NB600-302-img0006.jpg)
![Western Blot: c-Myc Antibody (9E10) - BSA Free [NB600-302] - Western blotting analysis of unsorted (W) and sorted ROSl degrees w(L) and ROShigh(H) cells. Data shown are representative of at least two independent experiments.DyLight 650 conjugated version of this antibody used (NB600-302C). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25857523/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-BSA-Free-Western-Blot-NB600-302-img0026.jpg)
![Immunocytochemistry/Immunofluorescence: c-Myc Antibody (9E10) [NB600-302] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-c-Myc (9E10) at 10 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Immunocytochemistry-Immunofluorescence-NB600-302-img0011.jpg)
![Flow (Intracellular): c-Myc Antibody (9E10) [NB600-302] - An intracellular stain was performed on U-937 cells with c-Myc Antibody (9E10) NB600-302PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.. Using the PE format of this antibody.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Flow-Intracellular-NB600-302-img0024.jpg)
![Western Blot: c-Myc Antibody (9E10) [NB600-302] - Analysis of c-myc in Jurkat cell lysates using NB600-302.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Western-Blot-NB600-302-img0005.jpg)
![Western Blot: c-Myc Antibody (9E10) [NB600-302] - Flow cytometric analysis of ROS and the mitochondrial status. Western blotting analysis of unsorted (W) and sorted P1 and P2 cells. Data shown are representative of at least two independent experiments. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/ncomms7750) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Western-Blot-NB600-302-img0025.jpg)
![Flow Cytometry: c-Myc Antibody (9E10) [NB600-302] - An intracellular stain was performed on U-937 cells with c-Myc Antibody (9E10) NB600-302AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Flow-Cytometry-NB600-302-img0014.jpg)
![Flow Cytometry: c-Myc Antibody (9E10) [NB600-302] - An intracellular stain was performed on Jurkat cells with c-Myc Antibody (9E10) NB600-302R (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 550.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Flow-Cytometry-NB600-302-img0019.jpg)
![Flow (Intracellular): c-Myc Antibody (9E10) [NB600-302] - An intracellular stain was performed on U-937 cells with c-Myc Antibody (9E10) NB600-302F (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to FITC.. Using the FITC format of this antibody.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Flow-Intracellular-NB600-302-img0023.jpg)
![Western Blot: c-Myc Antibody (9E10) - BSA Free [NB600-302] - NLRP2 interacts with SCMC components TLE6, OOEP, FILIA & NLRP5.(A) NLRP2 was overexpressed with myc-tagged OOEP, TLE6, NLRP5 & FILIA in HEK293T cells for 48 hours, immunoprecipitated with anti-NLRP2 or IgG as negative control & immunoblotted with anti-myc. Top panel shows specificity of anti-NLRP2 IP & bottom panel shows that NLRP2 binds to OOEP, TLE6, FILIA & NLRP5. Uncropped, full length western blots have been provided in Supplementary Figure 5. (B) Whole-mount immunofluorescence co-staining with anti-NLRP2 (green) & DAPI (blue) for nuclear staining on Nlrp2+/+ oocytes & embryos at 2-, 4-,16-cell & morula stages revealed a predominantly SCMC-like localization for NLRP2. Scale bars represent 200 μm. (C) Co-staining with anti-TLE6 (green) & DAPI (blue) of paraffin-embedded oocyte sections reveals a typical cortical stain of TLE6 in oocytes of Nlrp2+/+ dams but a more intense & diffuse stain in oocytes of Nlrp2tm1a/tm1a dams. Scale bars represent 10 μm. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/srep44667), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-302_mouse-monoclonal-c-myc-antibody-9e10-310202416163779.jpg)
![Western Blot: LRRK2 Antibody [NB300-268] - Western blotting of LRRK2. Recombinant LRRK2 (arrowhead) from transfected (+) HEK 293T and M17 cells was specifically recognized by all four LRRK2 antibodies (Ab1, Ab2, Ab3, and Ab4) used in this study. LRRK2 was not recognized in non-transfected cells (-). Image collected and cropped by CiteAb from the following publication (//molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-1-17), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Western-Blot-NB300-268-img0023.jpg "<b>Independent Antibodies Validation. </b>Western Blot: LRRK2 Antibody [NB300-268] - Western blotting of LRRK2. Recombinant LRRK2 (arrowhead) from transfected (+) HEK 293T and M17 cells was specifically recognized by all four LRRK2 antibodies (Ab1, Ab2, Ab3, and Ab4) used in this study. LRRK2 was not recognized in non-transfected cells (-). Image collected and cropped by CiteAb from the following publication (//molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-1-17), licensed under a CC-BY license.")
![<b>Independent Antibodies Validation. </b>Immunohistochemistry-Frozen: LRRK2 Antibody [NB300-268] - Staining as described in PMID 24312256. Image from verified customer review.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunohistochemistry-Frozen-NB300-268-img0014.jpg)
![Western Blot: LRRK2 Antibody [NB300-268] - LRRK2 N-terminal sequences show increased aggregation. Western blots of cell lysates of SH-SY5Y cells transfected with indicated LRRK2 construct showed equal expression of the LRRK2 protein with anti-HA (top panel) or anti-C-terminal- (bottom panel) LRRK2 antibody. Equal lysate loading is indicated by Beta-actin loading control. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0045149) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Western-Blot-NB300-268-img0028.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody [NB300-268] - Specificity of immunostaining for LRRK2. Specificity of the antibodies used for immunocytochemistry was determined by performing adsorptions with the corresponding peptide sequences. Immunochemical localization of LBs (arrows) by Ab1 against LRRK2900-100 (left) was blocked using respective peptide antigens (right). Adjacent sections with LB within pigmented neurons from the substantia nigra of a case of PD were used. Scale bar: 20 um. Image collected and cropped by CiteAb from the following publication (//molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-1-17), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunohistochemistry-Paraffin-NB300-268-img0026.jpg)
![<b>Independent Antibodies Validation. </b>Immunohistochemistry-Paraffin: LRRK2 Antibody [NB300-268] - Immunocytochemistry of LRRK2 in PD using antibodies (Ab1, Ab4) raised against sequences corresponding to various regions shown on the schematic diagram of LRRK2 (red bars) were used on brainstem sections of PD. Scale bars: 10 um (top); E-L = 100 um (bottom). Image collected and cropped by CiteAb from the following publication (//molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-1-17), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunohistochemistry-Paraffin-NB300-268-img0025.jpg)
![Flow Cytometry: LRRK2 Antibody [NB300-268] - Analysis using the Alexa Fluor 647 conjugate of NB300-268. Staining of LRRK2 in normal human peripheral blood cells (anticoagulated Lithium-Heparin) using anti-LRRK2 antibody conjugated with AF647. The primary antibody was used at a dilution of 1:200 and incubated for 20 min at room temperature. Image from verified customer review.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Flow-Cytometry-NB300-268-img0019.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody [NB300-268] - LRRK2 accumulates in globules in alphaS tg mice. Triple immunofluorescence for alphaS, LRRK2 and Rab5B for basal ganglia in alphaS tg mice. LRRK2 and Rab5B were colocalized in axon terminal (arrow), but were not colocalized in the alphaS-globule (arrowhead) Scale bar = 10 um for all panels. Image collected and cropped by CiteAb from the following publication (//molecularbrain.biomedcentral.com/articles/10.1186/1756-6606-5-34), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunohistochemistry-Paraffin-NB300-268-img0024.jpg)
![Immunocytochemistry/Immunofluorescence: LRRK2 Antibody [NB300-268] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-LRRK2 Antibody NB300-268 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunocytochemistry-Immunofluorescence-NB300-268-img0031.jpg)
![Flow Cytometry: LRRK2 Antibody [NB300-268] - An intracellular stain was performed on U2OS cells with LRRK2 Antibody NB300-268 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/LRRK2-Antibody-Flow-Cytometry-NB300-268-img0030.jpg)
![Immunocytochemistry/Immunofluorescence: LRRK2 Antibody [NB300-268] - LRRK2 antibody was tested in SH-SY-5Y cells at a 1:200 dilution against DyLight 488 (Green). Alpha tubulin and nuclei were counterstained against DyLight 568 (Red), and DAPI (Blue), respectively.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunocytochemistry-Immunofluorescence-NB300-268-img0015.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody [NB300-268] - Staining of human brain, Putamen, Neurons and Glia using a 60X magnification.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunohistochemistry-Paraffin-NB300-268-img0020.jpg)
![Flow Cytometry: LRRK2 Antibody [NB300-268] - An intracellular stain was performed on U2OS cells with LRRK Antibody NB300-268AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Flow-Cytometry-NB300-268-img0022.jpg)
![Flow Cytometry: LRRK2 Antibody [NB300-268] - An intracellular stain was performed on Neuro2a cells with LRRK2 Antibody NB300-268 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/LRRK2-Antibody-Flow-Cytometry-NB300-268-img0029.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - Western blotting of LRRK2. A. Recombinant LRRK2 (arrowhead) from transfected (+) HEK 293T & M17 cells was specifically recognized by all four LRRK2 antibodies (Ab1, Ab2, Ab3, & Ab4) used in this study. LRRK2 was not recognized in non-transfected cells (-). B. Recombinant LRRK2 (arrowhead) from transfected M17 cells is detected by anti-LRRK2 Ab4 (lane 1), but not after absorption of the antibody with its peptide antigen (lane 2). Brain LRRK2 was recognized by anti-LRRK2 Ab4 in two controls (lanes 3 & 4) & two PD cases (lanes 5 & 6). Cell lysates (10 μg protein) & brain homogenates (100 μg protein) were prepared & loaded on 6% SDS-PAGE gels for Western blot analysis using anti-LRRK2 antibodies Ab1–Ab4 in (A) & Ab4 in (B). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415371926.jpg)
![Flow Cytometry: LRRK2 Antibody - BSA Free [NB300-268] - Deletion of LRRK2 attenuates Mn-induced apoptosis & cell death in RAW 264.7 cells.(A) LRRK2 WT or KO RAW 264.7 cells were treated with Mn (250 μM) for the designated times, followed by flow cytometry analysis to determine Mn-induced apoptosis. Both early & late apoptotic cells (Q2 & Q3) were measured. (B) At the end of Mn exposure, cell viability was determined by MTT assay. @@@, p < 0.001; ###, p < 0.001; ***, p < 0.001 compared to the control (one-way ANOVA followed by Tukey’s post hoc test; n = 3, for apoptosis assay; n = 6, for MTT assay). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241539739.jpg)
![Immunocytochemistry/ Immunofluorescence: LRRK2 Antibody - BSA Free [NB300-268] - LRRK2 accumulates in globules in alpha S tg mice. (a & b) Double immunofluorescence for alpha S with parkin, PINK1, DJ-1, LRRK2, or negative control (the immunopeptide-preabsorbed anti-LRRK2 antibody) in alpha S tg mice (a) & P123H beta S tg mice (b). Note that alpha S-globules were immunopositive for LRRK2 (~79%, n = 22), whereas P123H beta S globules were negative for LRRK2. Representative images are shown for the thalamus ( alpha S) & basal ganglia (P123H beta S). Scale bar = 5 μm for all panels. (c) Triple immunofluorescence for alpha S, LRRK2 & Rab5B for basal ganglia in alpha S tg mice. LRRK2 & Rab5B were colocalized in axon terminal (arrow), but were not colocalized in the alpha S-globule (arrowhead) Scale bar = 10 μm for all panels. Image collected & cropped by CiteAb from the following publication (//molecularbrain.biomedcentral.com/articles/10.1186/1756-6606-5-34), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241538242.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Specificity of immunostaining for LRRK2. Specificity of the antibodies used for immunocytochemistry was determined by performing adsorptions with the corresponding peptide sequences. Immunochemical localization of LBs (arrows) by Ab4 against LRRK22500–2527 (A) & Ab1 against LRRK2900–100 (C) was blocked using respective peptide antigens (B & D). Adjacent sections with LB within pigmented neurons from the substantia nigra of a case of PD were used. Scale bar: 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415392599.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in DLB. Cortical LBs (arrows) in DLB were positive for LRRK2 using both Ab4 against LRRK22500–2527 (A), & Ab1 against LRRK2900–100 (B). Neuronal cytoplasm (C) was also strongly labelled throughout the cortex by Ab4 & with a consistently more granular pattern by Ab1 (inset in C) in cases of DLB. Control cases display similar, though less intense neuronal labeling (D). Biochemically purified cortical LBs were strongly positive for staining by Ab4 (E) as well as by anti-alpha -synuclein (F), while they were unstained when omitting primary antibody (G). Large vessels (H) were also intensely labelled by Ab4. Scale bars: A, B = 25 μm; C, D = 100 μm; E-G = 25 μm; H = 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415304221.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in DLB. Cortical LBs (arrows) in DLB were positive for LRRK2 using both Ab4 against LRRK22500–2527 (A), & Ab1 against LRRK2900–100 (B). Neuronal cytoplasm (C) was also strongly labelled throughout the cortex by Ab4 & with a consistently more granular pattern by Ab1 (inset in C) in cases of DLB. Control cases display similar, though less intense neuronal labeling (D). Biochemically purified cortical LBs were strongly positive for staining by Ab4 (E) as well as by anti-alpha -synuclein (F), while they were unstained when omitting primary antibody (G). Large vessels (H) were also intensely labelled by Ab4. Scale bars: A, B = 25 μm; C, D = 100 μm; E-G = 25 μm; H = 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241534387.jpg)
![Immunocytochemistry/ Immunofluorescence: LRRK2 Antibody - BSA Free [NB300-268] - LRRK2 accumulates in globules in alpha S tg mice. (a & b) Double immunofluorescence for alpha S with parkin, PINK1, DJ-1, LRRK2, or negative control (the immunopeptide-preabsorbed anti-LRRK2 antibody) in alpha S tg mice (a) & P123H beta S tg mice (b). Note that alpha S-globules were immunopositive for LRRK2 (~79%, n = 22), whereas P123H beta S globules were negative for LRRK2. Representative images are shown for the thalamus ( alpha S) & basal ganglia (P123H beta S). Scale bar = 5 μm for all panels. (c) Triple immunofluorescence for alpha S, LRRK2 & Rab5B for basal ganglia in alpha S tg mice. LRRK2 & Rab5B were colocalized in axon terminal (arrow), but were not colocalized in the alpha S-globule (arrowhead) Scale bar = 10 μm for all panels. Image collected & cropped by CiteAb from the following publication (//molecularbrain.biomedcentral.com/articles/10.1186/1756-6606-5-34), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241517133.jpg)
![Immunocytochemistry/ Immunofluorescence: LRRK2 Antibody - BSA Free [NB300-268] - LRRK2 accumulates in globules in alpha S tg mice. (a & b) Double immunofluorescence for alpha S with parkin, PINK1, DJ-1, LRRK2, or negative control (the immunopeptide-preabsorbed anti-LRRK2 antibody) in alpha S tg mice (a) & P123H beta S tg mice (b). Note that alpha S-globules were immunopositive for LRRK2 (~79%, n = 22), whereas P123H beta S globules were negative for LRRK2. Representative images are shown for the thalamus ( alpha S) & basal ganglia (P123H beta S). Scale bar = 5 μm for all panels. (c) Triple immunofluorescence for alpha S, LRRK2 & Rab5B for basal ganglia in alpha S tg mice. LRRK2 & Rab5B were colocalized in axon terminal (arrow), but were not colocalized in the alpha S-globule (arrowhead) Scale bar = 10 μm for all panels. Image collected & cropped by CiteAb from the following publication (//molecularbrain.biomedcentral.com/articles/10.1186/1756-6606-5-34), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415304292.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - Western blotting of LRRK2. A. Recombinant LRRK2 (arrowhead) from transfected (+) HEK 293T & M17 cells was specifically recognized by all four LRRK2 antibodies (Ab1, Ab2, Ab3, & Ab4) used in this study. LRRK2 was not recognized in non-transfected cells (-). B. Recombinant LRRK2 (arrowhead) from transfected M17 cells is detected by anti-LRRK2 Ab4 (lane 1), but not after absorption of the antibody with its peptide antigen (lane 2). Brain LRRK2 was recognized by anti-LRRK2 Ab4 in two controls (lanes 3 & 4) & two PD cases (lanes 5 & 6). Cell lysates (10 μg protein) & brain homogenates (100 μg protein) were prepared & loaded on 6% SDS-PAGE gels for Western blot analysis using anti-LRRK2 antibodies Ab1–Ab4 in (A) & Ab4 in (B). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241536376.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in DLB. Cortical LBs (arrows) in DLB were positive for LRRK2 using both Ab4 against LRRK22500–2527 (A), & Ab1 against LRRK2900–100 (B). Neuronal cytoplasm (C) was also strongly labelled throughout the cortex by Ab4 & with a consistently more granular pattern by Ab1 (inset in C) in cases of DLB. Control cases display similar, though less intense neuronal labeling (D). Biochemically purified cortical LBs were strongly positive for staining by Ab4 (E) as well as by anti-alpha -synuclein (F), while they were unstained when omitting primary antibody (G). Large vessels (H) were also intensely labelled by Ab4. Scale bars: A, B = 25 μm; C, D = 100 μm; E-G = 25 μm; H = 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415175254.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in DLB. Cortical LBs (arrows) in DLB were positive for LRRK2 using both Ab4 against LRRK22500–2527 (A), & Ab1 against LRRK2900–100 (B). Neuronal cytoplasm (C) was also strongly labelled throughout the cortex by Ab4 & with a consistently more granular pattern by Ab1 (inset in C) in cases of DLB. Control cases display similar, though less intense neuronal labeling (D). Biochemically purified cortical LBs were strongly positive for staining by Ab4 (E) as well as by anti-alpha -synuclein (F), while they were unstained when omitting primary antibody (G). Large vessels (H) were also intensely labelled by Ab4. Scale bars: A, B = 25 μm; C, D = 100 μm; E-G = 25 μm; H = 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415345320.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in DLB. Cortical LBs (arrows) in DLB were positive for LRRK2 using both Ab4 against LRRK22500–2527 (A), & Ab1 against LRRK2900–100 (B). Neuronal cytoplasm (C) was also strongly labelled throughout the cortex by Ab4 & with a consistently more granular pattern by Ab1 (inset in C) in cases of DLB. Control cases display similar, though less intense neuronal labeling (D). Biochemically purified cortical LBs were strongly positive for staining by Ab4 (E) as well as by anti-alpha -synuclein (F), while they were unstained when omitting primary antibody (G). Large vessels (H) were also intensely labelled by Ab4. Scale bars: A, B = 25 μm; C, D = 100 μm; E-G = 25 μm; H = 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415384173.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - LRRK2 deletion attenuates Mn-induced pro-apoptotic protein levels.(A) After cells (LRRK2 WT & LRRK2 KO) were exposed to Mn (250 μM) for up to 24 h, total protein was extracted & followed by western blot analysis to determine protein levels of Bax & Daxx. beta -actin was used as a loading control. (B) The expression levels of Bax & Daxx modulated by Mn were quantified relative to its control levels in LRRK2 WT & KO cells. **, p < 0.01; ***, p < 0.001 (one-way ANOVA followed by Tukey’s post hoc test; n = 3). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241535611.jpg)
![Immunocytochemistry/ Immunofluorescence: LRRK2 Antibody - BSA Free [NB300-268] - The interaction & phosphorylation of LRRK2 & LC1. (A) Cellular co-localisation of endogenous LRRK2 & MAP1B (LC1). SKNSH cells were labelled with LRRK2 (green) & LC1 (red) antibodies & signals were detected by immunofluorescence. Detailed figure in Additional file 1. (B) LRRK2 kinase assay. The LRRK2 wild-typed (WT) kinase interacted & phosphorylated the LC1 domain unlike the LRRK2 kinase-dead protein. (C) Western blotting of LRRK2 & LC1 proteins after a kinase assay. Both LRRK2 & LC1 proteins were probed for phospho-threonine & phospho-serine signals respectively. Image collected & cropped by CiteAb from the following publication (//molecularbrain.biomedcentral.com/articles/10.1186/1756-6606-7-29), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415382414.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - Mn increases LRRK2 kinase activity & expression in RAW 264.7 & HMC3 cells.(A) Two-hundred (200) μg of protein were collected from cell lysates, followed by western blot analysis to determine the presence of LRRK2 in LRRK2 WT, KO RAW 264.7 & HMC3 cells. beta -actin was used as a loading control. (B,C) LRRK2 WT or HMC3 cells were treated with Mn (250 μM) for the designated times, followed by protein extraction & western blot analysis as described in the Methods section. Protein levels of LRRK2 & phosphorylated LRRK2 (S1292) in LRRK2 WT RAW 264.7 (B) & HMC3 (C) cells were quantified. (D,E) Effect of Mn on LRRK2 mRNA levels in LRRK2 WT RAW 264.7 (D) & HMC3 (E) cells were assessed as described in the Methods section. GAPDH was used as a loading control. (F) After pre-treatment with LRRK2 inhibitors GSK (1 μM) & MLi-2 (50 nM) for 90 min, RAW 264.7 cells were exposed to Mn (250 μM) for 20 min, followed by western blot analysis to detect phosphorylation of LRRK2 (S1292). ###, p < 0.001; *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared to the control (one-way ANOVA followed by Tukey’s post hoc test; n = 3). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241621814.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in PD. Four antibodies raised against sequences corresponding to various regions shown on the schematic diagram of LRRK2 (red bars) were used on brainstem sections of PD (A-H) & age-matched controls (I-L). Intense immunolabeling of brainstem LBs in cases of PD was seen with Ab1 against LRRK2900–100 (A) & Ab4 against LRRK22500–2527(D). Both rim (A & D) & core (inset in D) of LBs were recognized. In contrast, LBs were not labelled in any case using antibodies directed against LRRK21246–1265 (Ab2, B) or LRRK21838–2133 (Ab3, C), for which the antigenic sites are located within the folded domains. The cell bodies of both pigmented & no-pigmented neurons (arrows) as well as axons (arrowheads) contain LRRK2, seen only using antibodies against sites outside the folded domains (Ab1, E & Ab4, H). In contrast, Ab4 staining was much less intense in control tissue (L). The muscle layer of both large & small vessels was consistently found to contain high levels of LRRK2 in almost all PD cases (seen in E, G, & H) & strikingly the vessels are the only structure immunolabeled with Ab3 recognizing LRRK21838–2133 in all cases studied (G & K). Ab2 to LRRK21246–1265 did not recognize LBs, cell bodies or vessels in any case (B, F, & J). Scale bars: A-D & inset = 10 μm; E-L = 100 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202416205168.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in PD. Four antibodies raised against sequences corresponding to various regions shown on the schematic diagram of LRRK2 (red bars) were used on brainstem sections of PD (A-H) & age-matched controls (I-L). Intense immunolabeling of brainstem LBs in cases of PD was seen with Ab1 against LRRK2900–100 (A) & Ab4 against LRRK22500–2527(D). Both rim (A & D) & core (inset in D) of LBs were recognized. In contrast, LBs were not labelled in any case using antibodies directed against LRRK21246–1265 (Ab2, B) or LRRK21838–2133 (Ab3, C), for which the antigenic sites are located within the folded domains. The cell bodies of both pigmented & no-pigmented neurons (arrows) as well as axons (arrowheads) contain LRRK2, seen only using antibodies against sites outside the folded domains (Ab1, E & Ab4, H). In contrast, Ab4 staining was much less intense in control tissue (L). The muscle layer of both large & small vessels was consistently found to contain high levels of LRRK2 in almost all PD cases (seen in E, G, & H) & strikingly the vessels are the only structure immunolabeled with Ab3 recognizing LRRK21838–2133 in all cases studied (G & K). Ab2 to LRRK21246–1265 did not recognize LBs, cell bodies or vessels in any case (B, F, & J). Scale bars: A-D & inset = 10 μm; E-L = 100 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202416205158.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - Mn increases LRRK2 kinase activity & expression in RAW 264.7 & HMC3 cells.(A) Two-hundred (200) μg of protein were collected from cell lysates, followed by western blot analysis to determine the presence of LRRK2 in LRRK2 WT, KO RAW 264.7 & HMC3 cells. beta -actin was used as a loading control. (B,C) LRRK2 WT or HMC3 cells were treated with Mn (250 μM) for the designated times, followed by protein extraction & western blot analysis as described in the Methods section. Protein levels of LRRK2 & phosphorylated LRRK2 (S1292) in LRRK2 WT RAW 264.7 (B) & HMC3 (C) cells were quantified. (D,E) Effect of Mn on LRRK2 mRNA levels in LRRK2 WT RAW 264.7 (D) & HMC3 (E) cells were assessed as described in the Methods section. GAPDH was used as a loading control. (F) After pre-treatment with LRRK2 inhibitors GSK (1 μM) & MLi-2 (50 nM) for 90 min, RAW 264.7 cells were exposed to Mn (250 μM) for 20 min, followed by western blot analysis to detect phosphorylation of LRRK2 (S1292). ###, p < 0.001; *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared to the control (one-way ANOVA followed by Tukey’s post hoc test; n = 3). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202416205187.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - Mn increases LRRK2 kinase activity & expression in RAW 264.7 & HMC3 cells.(A) Two-hundred (200) μg of protein were collected from cell lysates, followed by western blot analysis to determine the presence of LRRK2 in LRRK2 WT, KO RAW 264.7 & HMC3 cells. beta -actin was used as a loading control. (B,C) LRRK2 WT or HMC3 cells were treated with Mn (250 μM) for the designated times, followed by protein extraction & western blot analysis as described in the Methods section. Protein levels of LRRK2 & phosphorylated LRRK2 (S1292) in LRRK2 WT RAW 264.7 (B) & HMC3 (C) cells were quantified. (D,E) Effect of Mn on LRRK2 mRNA levels in LRRK2 WT RAW 264.7 (D) & HMC3 (E) cells were assessed as described in the Methods section. GAPDH was used as a loading control. (F) After pre-treatment with LRRK2 inhibitors GSK (1 μM) & MLi-2 (50 nM) for 90 min, RAW 264.7 cells were exposed to Mn (250 μM) for 20 min, followed by western blot analysis to detect phosphorylation of LRRK2 (S1292). ###, p < 0.001; *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared to the control (one-way ANOVA followed by Tukey’s post hoc test; n = 3). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241621239.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - Mn increases LRRK2 kinase activity & expression in RAW 264.7 & HMC3 cells.(A) Two-hundred (200) μg of protein were collected from cell lysates, followed by western blot analysis to determine the presence of LRRK2 in LRRK2 WT, KO RAW 264.7 & HMC3 cells. beta -actin was used as a loading control. (B,C) LRRK2 WT or HMC3 cells were treated with Mn (250 μM) for the designated times, followed by protein extraction & western blot analysis as described in the Methods section. Protein levels of LRRK2 & phosphorylated LRRK2 (S1292) in LRRK2 WT RAW 264.7 (B) & HMC3 (C) cells were quantified. (D,E) Effect of Mn on LRRK2 mRNA levels in LRRK2 WT RAW 264.7 (D) & HMC3 (E) cells were assessed as described in the Methods section. GAPDH was used as a loading control. (F) After pre-treatment with LRRK2 inhibitors GSK (1 μM) & MLi-2 (50 nM) for 90 min, RAW 264.7 cells were exposed to Mn (250 μM) for 20 min, followed by western blot analysis to detect phosphorylation of LRRK2 (S1292). ###, p < 0.001; *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared to the control (one-way ANOVA followed by Tukey’s post hoc test; n = 3). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241621810.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - LRRK2 kinase inhibition blocks Tat-induced S935 phosphorylation & inflammatory cytokine expression in BV-2 cells. (A) Western blot depicting pS935-LRRK2 & total LRRK2 protein levels 12 hours after saline or Tat-treatment ± LRRK2 kinase inhibition (LRRK2i). (B) Tat treatment significantly increased pS935-LRRK2, which was attenuated by LRRK2i. (C) We measured TNF-alpha , IL-6, MCP-1 & IL-10 mRNA levels by qRT-PCR 12 hours post saline or Tat treatment ± LRRK2i. LRRK2i attenuated Tat-induced TNF-alpha , IL-6, MCP-1 & IL-10 expression for all groups (*P <0.05, ***P <0.001, one way ANOVA, Newman-Keuls post-test). ANOVA, analysis of variance; LRRK2, leucine-rich repeat kinase2; pS935, phosphorylation of serine 935; Tat, trans activator of transcription. Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-9-261), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202416212357.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in PD. Four antibodies raised against sequences corresponding to various regions shown on the schematic diagram of LRRK2 (red bars) were used on brainstem sections of PD (A-H) & age-matched controls (I-L). Intense immunolabeling of brainstem LBs in cases of PD was seen with Ab1 against LRRK2900–100 (A) & Ab4 against LRRK22500–2527(D). Both rim (A & D) & core (inset in D) of LBs were recognized. In contrast, LBs were not labelled in any case using antibodies directed against LRRK21246–1265 (Ab2, B) or LRRK21838–2133 (Ab3, C), for which the antigenic sites are located within the folded domains. The cell bodies of both pigmented & no-pigmented neurons (arrows) as well as axons (arrowheads) contain LRRK2, seen only using antibodies against sites outside the folded domains (Ab1, E & Ab4, H). In contrast, Ab4 staining was much less intense in control tissue (L). The muscle layer of both large & small vessels was consistently found to contain high levels of LRRK2 in almost all PD cases (seen in E, G, & H) & strikingly the vessels are the only structure immunolabeled with Ab3 recognizing LRRK21838–2133 in all cases studied (G & K). Ab2 to LRRK21246–1265 did not recognize LBs, cell bodies or vessels in any case (B, F, & J). Scale bars: A-D & inset = 10 μm; E-L = 100 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241621837.jpg)
![Flow Cytometry: LRRK2 Antibody - BSA Free [NB300-268] - Inhibition of LRRK2 kinase activity attenuates Mn-induced apoptosis.(A) After pre-treatment with GSK (1 μM) for 90 min, cells (HMC3) were exposed to Mn (250 μM) for the designated time periods, followed by annexin V & PI staining & flow cytometry analysis to determine apoptosis. Early & late apoptotic cells (Q2 & Q3) were analyzed. (B,C) After pre-treatment with GSK (1 μM) for 90 min, cells (LRRK2 WT RAW 264.7 & HMC3) were exposed to Mn for designated time periods, followed by the MTT assay to determine cell viability, as described in the Methods section, (@@@, p < 0.001; *, p < 0.05; ***, p < 0.001 compared to the control (one-way ANOVA followed by Tukey’s post hoc test; n = 3, apoptosis assay; n = 6, MTT assay). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241621844.jpg)
![Western Blot: Dcp1a Antibody (3G4) [H00055802-M06] - Western Blot analysis of DCP1A expression in IMR-32 ( Cat # L008V1 ).](http://images.novusbio.com/fullsize/Dcp1a-Antibody-3G4-Western-Blot-H00055802-M06-img0001.jpg "Western Blot: Dcp1a Antibody (3G4) [H00055802-M06] - Western Blot analysis of DCP1A expression in IMR-32 ( Cat # L008V1 ).")
![Immunocytochemistry/Immunofluorescence: Dcp1a Antibody (3G4) [H00055802-M06] - Anti-Dcp1alpha antibody recognizes its antigen. SCG neurons shown overexpressing GFP-Dcp1alpha and immunostained with anti-Dcp1alpha antibody. Note that all GFP-Dcp1alpha granules are recognized by anti-Dcp1alpha antibody. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2013297), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Dcp1a-Antibody-3G4-Immunocytochemistry-Immunofluorescence-H00055802-M06-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: Dcp1a Antibody (3G4) [H00055802-M06] - Analysis of monoclonal antibody to DCP1A on HeLa cell. Antibody concentration 10 ug/ml](http://images.novusbio.com/fullsize/Dcp1a-Antibody-3G4-Immunocytochemistry-Immunofluorescence-H00055802-M06-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: Dcp1a Antibody (3G4) [H00055802-M06] - The MIWI2/MAEL granule is a modified P-body. Localization of P-bodies in gonocytes. Cross section seminiferous tubule from wild-type testis (E18.5) were probed with antibodies against DCP1a. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pgen.1000764), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Dcp1a-Antibody-3G4-Immunocytochemistry-Immunofluorescence-H00055802-M06-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: Dcp1a Antibody (3G4) [H00055802-M06] - Localization of P-bodies in gonocytes. Co-localization of MAEL and P-body component DCP1a in piP-bodies. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pgen.1000764), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Dcp1a-Antibody-3G4-Immunocytochemistry-Immunofluorescence-H00055802-M06-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: Dcp1a Antibody (3G4) [H00055802-M06] - Anti-Dcp1alpha antibody recognizes its antigen. SCG neuron shown overexpressing GFP-Dcp1alpha. Note that all GFP-Dcp1alpha granules are recognized by anti-Dcp1alpha antibody. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2013297), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Dcp1a-Antibody-3G4-Immunocytochemistry-Immunofluorescence-H00055802-M06-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: Dcp1a Antibody (3G4) [H00055802-M06] - Deconvoluted merged stacks of confocal microscopic images of typical neurons colabeled with anti-Dcp1alpha antibodies, the marker for the P-bodies. Note that the granules do not colocalize. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2013297), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Dcp1a-Antibody-3G4-Immunocytochemistry-Immunofluorescence-H00055802-M06-img0012.jpg)
![ELISA: Dcp1a Antibody (3G4) [H00055802-M06] - Detection limit for recombinant GST tagged DCP1A is approximately 0.1ng/ml as a capture antibody.](http://images.novusbio.com/fullsize/Dcp1a-Antibody-3G4-ELISA-H00055802-M06-img0007.jpg)
![Immunocytochemistry/ Immunofluorescence: Dcp1a Antibody (3G4) [H00055802-M06] - OTUD4 is recruited to stress granules. (A) Immunofluorescence of OTUD4 (shown in red) in SH-SY5Y cells that were either untreated, arsenite-treated (30 min, 0.5 mM) or heat-shocked (42°C, 1 h). Cells were co-stained for the stress granule marker protein TIA1 (green) & DAPI as a nuclear marker (blue). OTUD4 is redistributed to granular structures upon arsenite & heat-shock treatment. Granules also contain TIA1 & are considered as stress granules. Scale bar: 20 µm. The experiment was repeated two times. (B) Exogenously expressed FLAG–OTUD4 is recruited to stress granules in HeLa cells. Transfected cells were arsenite-treated (0.5 mM) for 40 min or left untreated & co-stained with anti-FLAG (red) & anti-G3BP1 antibodies (green). Nuclei are shown in blue (DAPI). Scale bar: 20 µm. The experiment was done at least three times. (C) OTUD4 granules do not colocalize with P-bodies. Shown is immunofluorescence of HeLa cells (untreated or 0.5 mM arsenite for 30 min) stained with anti-OTUD4 (red) & anti-DCP1a (green) antibodies. Scale bar: 20 µm. The experiment was performed two times. (D) OTUD4 granules contain mRNA. HeLa cells were treated with arsenite (0.5 mM) for 1 h. FISH was carried out with Cy3-labeled oligo(dT) (red), & cells were co-stained with anti-OTUD4 (shown in green). Scale bar: 20 µm. A representative image from four independent experiments is shown. (E) Scheme illustrating OTUD4 fragments used in F, numbers indicate amino acid borders of expression constructs. IDR, intrinsically disordered region. (F) HeLa cells were transfected with EGFP-tagged OTUD4 expression constructs as shown in E) & treated with arsenite (0.5 mM for 30 min) or left untreated to monitor intrinsic ability to form granules. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31138677), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00055802-m06_mouse-monoclonal-dcp1a-antibody-3g4-310202415483610.jpg)
![Immunocytochemistry/Immunofluorescence: TPX2 Antibody [NB500-179] - Analysis of TPX2 at the mitotic spindle microtubules and poles in a HeLa metaphase cell. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/TPX2-Antibody-Immunocytochemistry-Immunofluorescence-NB500-179-img0004.jpg "Immunocytochemistry/Immunofluorescence: TPX2 Antibody [NB500-179] - Analysis of TPX2 at the mitotic spindle microtubules and poles in a HeLa metaphase cell. ICC/IF image submitted by a verified customer review.")
![Flow Cytometry: TPX2 Antibody [NB500-179] - RHAMM is not a cell surface but an intracellular cytoskeletal protein in mouse embryonic stem (ES) cells. (C) Alcohol permeabilized mouse ES cells, however, were strongly positive for both RHAMM and the intracellular positive control protein TPX2 (right panel). Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0073548) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TPX2-Antibody-Flow-Cytometry-NB500-179-img0005.jpg)
![Western Blot: TPX2 Antibody [NB500-179] - Analysis of TPX2 expression in 1) HeLa, 2) Ntera2, 3) K-562 and 4) Raji whole cell lysates using NB500-179.](http://images.novusbio.com/fullsize/TPX2-Antibody-Western-Blot-NB500-179-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: TPX2 Antibody [NB500-179] - Staining of HeLa cells fixed in 3.5% paraformaldehyde using NB 500-179 (1:1,000). Nuclear staining during interphase and spindle staining during mitosis.](http://images.novusbio.com/fullsize/TPX2-Antibody-Immunocytochemistry-Immunofluorescence-NB500-179-img0003.jpg)
![Simple Western: TPX2 Antibody [NB500-179] - Lane view shows a specific band for TPX2 using HeLa cell lysate and antibody at 1:250. Electropherogram image of corresponding Simple Western lane view. Image reported by internal validation.](http://images.novusbio.com/fullsize/TPX2-Antibody-Simple-Western-NB500-179-img0006.jpg)
![Immunocytochemistry/ Immunofluorescence: TPX2 Antibody [NB500-179] - Depletion of TPX2 or Aurora-A reduces cell viability of BRCA2-deficient breast cancer cells. a HCC1806-shBRCA2dox, HCC38-shBRCA2dox, SUM149-shBRCA2dox, & MB231-shBRCA2dox were grown on coverslips & treated with doxycycline (3 days) and/or irradiated (IR, 5 Gy) as indicated. Subsequently, cells were stained for RAD51 & gamma H2AX. Scale bars represent 5 μm. b Quantification of results from a. Percentages of cells with ≥5 RAD51 foci per nucleus are indicated (n ≥ 31). c Percentages of cell survival of doxycycline-treated cells vs untreated cells, transfected with indicated siRNAs. Unpaired two-tailed t tests were used to test for statistical significance (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). d BT-549 cells were transfected with siTPX2 or control siRNA (CTR). Cells were grown on coverslips for 3 days after which they were incubated with EdU conjugated to azide-Alexa 488 (10 μM) for 15 min. Subsequently, cells were fixed & stained for 53BP1 & gamma H2AX. Amounts of 53BP1 & gamma H2AX foci per cell of at least 30 EdU-positive cells were counted. Means & standard deviations are depicted. Mann–Whitney U tests were used to analyze statistical significance (*p ≤ 0.05, ** = p ≤ 0.01, ***p ≤ 0.001, ns not significant). e BT-549 cells were transfected as in d, irradiated (IR, 5 Gy), & fixated 0.5 or 6 h after irradiation. Amounts of 53BP1 & gamma H2AX foci per cell were counted. Means & standard deviations are depicted. Mann–Whitney U tests were used to analyze statistical significance (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ns = not significant) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30177840), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-179_rabbit-polyclonal-tpx2-antibody-31020241616051.jpg)
![Immunocytochemistry/ Immunofluorescence: TPX2 Antibody [NB500-179] - TPX2 depletion preferentially affects cell viability in BRCA2-deficient cancer cells. a BT-549-shBRCA2dox cells were left untreated or were treated with doxycycline (2 or 4 days), & subsequently harvested for western blotting for BRCA2 & actin. b BT-549-shBRCA2dox cells were treated as in panel A, & mRNA expression levels of BRCA2 were analyzed relative to GAPDH using qRT-PCR. c BT-549-shBRCA2dox cells were grown on coverslips & treated with doxycycline (3 days) and/or irradiated (IR, 5 Gy) as indicated. At 3 h after irradiation, cells were fixed & analyzed for RAD51 & gamma H2AX foci formation. Scale bars represent 5 μm. d Percentages of cells with ≥5 RAD51 foci per nucleus are indicated. (n ≥ 50 per condition). e BT-549-shBRCA2dox cells were treated with doxycycline (3 days) & were subsequently transfected with indicated siRNAs. A total of 30,000 cells were plated 48 h following transfection. Viable cells were counted 5 days later. Percentages of cell survival of doxycycline-treated vs untreated cells are depicted. Error bars indicate standard deviations of two experimental replicates. Unpaired two-tailed t tests were used to test for statistical significance (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30177840), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-179_rabbit-polyclonal-tpx2-antibody-310202416171435.jpg)
![Immunohistochemistry: Collagen III alpha 1/COL3A1 Antibody [NB600-594] - Tissue: right lobe of the liver section. A:Central Vein (CV) fibrosis, B: Non-fibrotic CV, C: Perisinusodial fibrosis, D: Non-fibrotic area, E: Protat tract fibrosis, F: Septal fibrosis (arrow). Fixation: FFPE. Antigen retrieval: not required. Primary antibody: Anti-collagen type I at 1:500 for 4 degrees Celsius for 24hr. Secondary antibody: Peroxidase biotin-streptavidin rabbit secondary antibody at 1:10,000 for 45 min at RT. Localization: Anti-collagen type III is intra and extracellular. Staining: 3.3'-diaminobenzidine tetrahydrochloride was used as the chromogen. Nuclei were counterstained purple with hematoxylin.](http://images.novusbio.com/fullsize/Collagen-III-alpha-1-COL3A1-Antibody-Immunohistochemistry-NB600-594-img0018.jpg "Immunohistochemistry: Collagen III alpha 1/COL3A1 Antibody [NB600-594] - Tissue: right lobe of the liver section. A:Central Vein (CV) fibrosis, B: Non-fibrotic CV, C: Perisinusodial fibrosis, D: Non-fibrotic area, E: Protat tract fibrosis, F: Septal fibrosis (arrow). Fixation: FFPE. Antigen retrieval: not required. Primary antibody: Anti-collagen type I at 1:500 for 4 degrees Celsius for 24hr. Secondary antibody: Peroxidase biotin-streptavidin rabbit secondary antibody at 1:10,000 for 45 min at RT. Localization: Anti-collagen type III is intra and extracellular. Staining: 3.3'-diaminobenzidine tetrahydrochloride was used as the chromogen. Nuclei were counterstained purple with hematoxylin.")
![Western Blot: Collagen III alpha 1/COL3A1 Antibody [NB600-594] - Lane 1: Human Collagen III Load: 100 ng per lane Primary antibody: Collagen III Antibody at 1:1000 o/n at 4C Secondary antibody: DyLight 649 Goat anti-rabbit at 1:20,000 for 30 min at RT Block: incubated with blocking buffer for 30 min at RT Predicted/Observed size: 138 kDa/138 kDa.](http://images.novusbio.com/fullsize/Collagen-III-alpha-1-COL3A1-Antibody-Western-Blot-NB600-594-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: Collagen III alpha 1/COL3A1 Antibody [NB600-594] - Human primary ventricular cardiac fibroblasts were stained with anti-Collagen III antibody. Cells were cultured for 3 days in DMEM with 10% fetal calf serum. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Collagen-III-alpha-1-COL3A1-Antibody-Immunocytochemistry-Immunofluorescence-NB600-594-img0012.jpg)
![Immunohistochemistry: Collagen III alpha 1/COL3A1 Antibody [NB600-594] - Staining in FFPE sections of human skin(left, dermis) with moderate to strong red staining and testis (right) where strong staining was observed within connective tissue between seminiferous tubules. The antibody showed strong extracellular staining within connective tissues across many organs with minimal background staining. Slides were steamed in 0.01 M sodium citrate buffer, pH 6.0 at 99-100C. 20 minutes for antigen retrieval.](http://images.novusbio.com/fullsize/Collagen-III-alpha-1-COL3A1-Antibody-Immunohistochemistry-NB600-594-img0016.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: Collagen III alpha 1/COL3A1 Antibody [NB600-594] - Immunodetection of ID3, COL1A2 and COL3A1 in human dermal fibroblasts subjected to treatment with or without cANGPTL4 (12 ug/mL) in the presence of TGFB1 (10 ng/mL). B-tubulin, as loading control, was from the same samples. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/s41598-017-05869-x) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Collagen-III-alpha-1-COL3A1-Antibody-Western-Blot-NB600-594-img0023.jpg)
![Immunohistochemistry: Collagen III alpha 1/COL3A1 Antibody [NB600-594] - Livers were harvested at 9 wpi, formalin-fixed, and then cryosectioned and stained for markers of inflammation and liver fibrosis. Maximum intensity projections of 12-17 um thick liver sections with immunofluorescently labeled nuclei (DAPI white) alpha-smooth muscle actin NBP2-34760APC (yellow), CD45 (red) and Collagen I NB600-408 (top) or Collagen III/COL3A1 NB600-594 (bottom) (blue) in the liver of uninfected or 9 wpi WT mice. Scale bars represent 50 um. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32973293/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Collagen III alpha 1-COL3A1 Antibody-Immunohistochemistry-NB600-594-img0024.jpg)
![Western Blot: Collagen III alpha 1/COL3A1 Antibody [NB600-594] - Western blot for COL3A1 protein with PVDF protein staining to control for protein loading. Image collected and cropped by CiteAb from the following publication (mdpi.com/2076-3921/6/4/87), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Collagen-III-alpha-1-COL3A1-Antibody-Western-Blot-NB600-594-img0019.jpg)
![Immunocytochemistry/Immunofluorescence: Collagen III alpha 1/COL3A1 Antibody [NB600-594] - Collagen III alpha 1 expression in HT-1080 cells. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Collagen-III-alpha-1-COL3A1-Antibody-Immunocytochemistry-Immunofluorescence-NB600-594-img0008.jpg)
![Immunohistochemistry-Paraffin: Collagen III alpha 1/COL3A1 Antibody [NB600-594] - Human lung tissue.](http://images.novusbio.com/fullsize/Collagen-III-alpha-1-COL3A1-Antibody-Immunohistochemistry-Paraffin-NB600-594-img0013.jpg)
![Immunohistochemistry-Paraffin: Collagen III alpha 1/COL3A1 Antibody [NB600-594] - Human lung tissue](http://images.novusbio.com/fullsize/Collagen-III-alpha-1-COL3A1-Antibody-Immunohistochemistry-Paraffin-NB600-594-img0014.jpg)
![Immunohistochemistry: Collagen III alpha 1/COL3A1 Antibody [NB600-594] - Collagen III (k, positive staining indicated by arrows) immunohistochemistry staining in 13 weeks old male offspring. Left panel = Sham, Middle panel = SE (cigarette smoke exposure), Right panel = SE+MQ (SE with MitoQ supplementation) bar = 50 um. Image collected and cropped by CiteAb from the following publication (mdpi.com/2072-6643/11/7/1669) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Collagen-III-alpha-1-COL3A1-Antibody-Immunohistochemistry-NB600-594-img0020.jpg)
![Immunohistochemistry: Collagen III alpha 1/COL3A1 Antibody [NB600-594] - Collagen I and collagen III accumulate in C57BL/6 mice in response to radiation. Bladder strips from irradiated and control mice were stained for collagen I or for collagen III and imaged using fluorescent microscopy. (a) Representative images (100 x 100 um) of each mouse strain and treatment group are provided for collagen I and collagen III immunofluorescence. Collagen I antibody (NB600-450, RRID:AB_522923) and Collagen III antibody (NB600-594, RRID:AB_10001330). Image collected and cropped by CiteAb from the following publication (onlinelibrary.wiley.com/doi/abs/10.14814/phy2.14377) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Collagen-III-alpha-1-COL3A1-Antibody-Immunohistochemistry-NB600-594-img0021.jpg)
![Western Blot: Collagen III alpha 1/COL3A1 Antibody [NB600-594] - SCE attenuates myocardial fibrosis in heart tissue after MI. (a) RT-qPCR analysis for mRNA expression of collagen type I alpha 1 (Col1a1), collagen type III alpha 1 (Col3a1), actin, alpha 2 smooth muscle (Acta2), Mmp2, & Mmp9 in the border area (BA) & remote area (RA) 7 days, 14 days, & 21 days after MI. (b) Immunoblot analysis of protein expressions of alpha -SMA, collagen I, & collagen III in RA & BA in the heart tissues 7 days, 14 days, & 21 days after MI. Data are from three independent experiments ((a), mean ± SEM) or are representative of three independent experiments with similar results (b). ∗P < 0.05 & ∗∗P < 0.01, ANOVA with LSD t-test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31275414), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-594_rabbit-polyclonal-collagen-iii-alpha-1-col3a1-antibody-31020241534373.jpg)
![Immunocytochemistry/ Immunofluorescence: Collagen III alpha 1/COL3A1 Antibody [NB600-594] - Collagen I & collagen III accumulate in C57BL/6 mice in response to radiation. Bladder strips from irradiated & control mice were stained for collagen I or for collagen III & imaged using fluorescent microscopy. (a) Representative images (100 x 100 µm) of each mouse strain & treatment group are provided for collagen I & collagen III immunofluorescence. (b–c) Percentage of tissue‐positive for collagen I or collagen III staining. Collagen I & III density is significantly elevated in C57BL/6 mice, but not in the C3H or BALB/c strains. Results are mean ± SD of n = 3–6 mice. Dashed line: ANOVA; Full line: multiple t‐test. **p < .01, *** p < .001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32109348), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-594_rabbit-polyclonal-collagen-iii-alpha-1-col3a1-antibody-310202415371941.jpg)
![Immunohistochemistry: Collagen III alpha 1/COL3A1 Antibody [NB600-594] - Number of collagen I‐expressing cells is increased in irradiated C57BL/6 detrusor. Bladder strips from irradiated & control mice were stained for collagen I or for collagen III mRNA & counterstained with methyl green. Collagen I & III mRNA (pink) is apparent in both control & irradiated bladder sections in all three mouse strains. The number of collagen I & III‐producing cells in the detrusor is represented in the bar graphs. The number of collagen I‐expressing cells is significantly elevated in C57BL/6 mice after irradiation. Dashed line separates the urothelium (U) & lamina propria (LP) from the detrusor muscle (D). Results are mean ± SD of n = 3–4 mice. Scale bar = 100 µm. op ≤ .08, * p < .05 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32109348), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-594_rabbit-polyclonal-collagen-iii-alpha-1-col3a1-antibody-310202415395941.jpg)
![Western Blot: Collagen III alpha 1/COL3A1 Antibody [NB600-594] - SCE attenuates fibrotic responses in CFs by inhibiting TGF-beta /Smad3 signaling activation. (a) RT-qPCR analysis of mRNA expression for genes of Col1a1, Col3a1, & Acta2 in cardiac fibroblasts (CFs) pretreated with different concentrations of SCE (5 μl/ml, 10 μl/ml, & 15 μl/ml) followed by TGF-beta stimulation (20 ng/ml) for 24 h. (b) RT-qPCR analysis of mRNA expression for genes of Col1a1, Col3a1, & Acta2 in CFs pretreated with SCE (10 μl/ml) followed by TGF-beta stimulation (20 ng/ml) for 12 h & 24 h. (c) RT-qPCR analysis of mRNA expression for genes of Smad2, Smad3, & Smad7 in CFs pretreated with SCE (10 μl/ml) followed by TGF-beta stimulation (20 ng/ml) for 12 h & 24 h. (d) Immunoblot analysis of expression of Smad2, Smad3, & Smad7 in CFs pretreated with SCE (10 μl/ml) followed by TGF-beta stimulation (20 ng/ml) for 24 h & 36 h. Data are from three independent experiments ((a)–(c), mean ± SEM) or are representative of three independent experiments with similar results (d). ∗P < 0.05 & ∗∗P < 0.01, Student's t-test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31275414), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-594_rabbit-polyclonal-collagen-iii-alpha-1-col3a1-antibody-31020241616022.jpg)
![Western Blot: c-Myc Antibody [NB600-335] - Detection of c-myc-tagged Protein by Western Blot. Samples: 200, 100, or 50 ng of E. coli whole cell lysate expressing a multi-tag fusion protein. Antibodies: Affinity purified, goat anti-c-myc antibody NB600-335 at 0.04 ug/ml (1:25,000). Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-335-img0006.jpg "Western Blot: c-Myc Antibody [NB600-335] - Detection of c-myc-tagged Protein by Western Blot. Samples: 200, 100, or 50 ng of E. coli whole cell lysate expressing a multi-tag fusion protein. Antibodies: Affinity purified, goat anti-c-myc antibody NB600-335 at 0.04 ug/ml (1:25,000). Detection: Chemiluminescence with an exposure time of 30 seconds.")
![Immunocytochemistry/Immunofluorescence: c-Myc Antibody [NB600-335] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton X-100. The cells were incubated with anti-c-Myc conjugated to Alexa Fluor 488 [NB600-335AF488] at 20 ug/mL for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective. Image using the Alexa Fluor 488 format of this antibody.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Immunocytochemistry-Immunofluorescence-NB600-335-img0007.jpg)
![Western Blot: c-Myc Antibody [NB600-335] - Analysis using the HRP conjugate of NB600-335. Detection of 200, 100, or 50 ng of E. coli whole cell lysate expressing a multi-tag fusion protein. Antibody used at 0.4 ug/mL (1:25,000).](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-335-img0005.jpg)
![Western Blot: GADD153/CHOP Antibody (9C8) [NB600-1335] - Ethanol feeding increases CHOP expression. Image from verified customer review.](http://images.novusbio.com/fullsize/GADD153-CHOP-Antibody-9C8-Western-Blot-NB600-1335-img0011.jpg "Western Blot: GADD153/CHOP Antibody (9C8) [NB600-1335] - Ethanol feeding increases CHOP expression. Image from verified customer review.")
![Immunohistochemistry-Paraffin: GADD153/CHOP Antibody (9C8) [NB600-1335] - FFPE tissue section of mouse brain using 1:100 dilution of GADD153/CHOP antibody. The signal was developed using HRP-DAB based detection method which followed counterstaining of the nuclei with hematoxylin. The antibody generated a cytoplasmic and nuclear staining of CHOP in various cell types in the tested section.](http://images.novusbio.com/fullsize/GADD153-CHOP-Antibody-9C8-Immunohistochemistry-Paraffin-NB600-1335-img0010.jpg)
![Flow Cytometry: GADD153/CHOP Antibody (9C8) [NB600-1335] - An intracellular stain was performed on SK-MEL-28 cells with GADD153/CHOP Antibody (9C8) NB600-1335 (blue) and a matched isotype control MAB004 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (84540, Thermo Fisher).](http://images.novusbio.com/fullsize/GADD153-CHOP-Antibody-9C8-Flow-Cytometry-NB600-1335-img0012.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: GADD153/CHOP Antibody (9C8) [NB600-1335] - GADD153/CHOP expression in HeLa cells treated with 2.5 ug/mL tunicamycin for 4 hours (Lane 1) and untreated (Lane 2).](http://images.novusbio.com/fullsize/GADD153-CHOP-Antibody-9C8-Western-Blot-NB600-1335-img0001.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: GADD153/CHOP Antibody (9C8) [NB600-1335] - Analysis of endogenous CHOP/GADD153 from primary human fibroblasts using NB600-1335. Lane 1: Untreated cells, Lane 2: Cells treated with tunicamycin for 10 hours.](http://images.novusbio.com/fullsize/GADD153-CHOP-Antibody-9C8-Western-Blot-NB600-1335-img0004.jpg)
![Western Blot: GADD153/CHOP Antibody (9C8) [NB600-1335] - Analysis of CHOP in rat heart tissue lysate. Image courtesy of product review submitted by Lee Hsiao-Wei.](http://images.novusbio.com/fullsize/GADD153-CHOP-Antibody-9C8-Western-Blot-NB600-1335-img0005.jpg)
![Immunohistochemistry-Paraffin: GADD153/CHOP Antibody (9C8) [NB600-1335] - FFPE tissue section of mouse brain using 1:100 dilution of GADD153/CHOP antibody. The signal was developed using HRP-DAB based detection method which followed counterstaining of the nuclei with hematoxylin. The antibody generated a cytoplasmic and nuclear staining of CHOP in various cell types in the tested section.](http://images.novusbio.com/fullsize/GADD153-CHOP-Antibody-9C8-Immunohistochemistry-Paraffin-NB600-1335-img0008.jpg)
![Simple Western: GADD153/CHOP Antibody (9C8) [NB600-1335] - Image shows a specific band for CHOP/GADD153 in 1.0 mg/mL of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/GADD153-CHOP-Antibody-9C8-Simple-Western-NB600-1335-img0007.jpg)